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The classical myeloproliferative neoplasms (MPNs) feature an overproduction of mature blood
elements. Phenotypic conversion, including transformation to myeloﬁbrosis (MF) in those with
antecedent ET and PV is a feared complication. Hypereosinophilic syndromes (HESs), especially those
with myeloproliferative variants, can display similar features, including organomegaly, marrow ﬁbrosis,
clonality, thrombotic tendencies, and acute myeloid leukemia (AML) transformation. However, this
group of illnesses is typically clinically and molecularly distinct from the classical MPNs. We report a
case of a 59-yr-old woman with complex hypereosinophilia in the setting of post-polycythemic
myeloﬁbrosis (post-PVMF), with multi-system end-organ damage characteristic of HES.
& 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Case
Twenty years prior to presentation to us, a 39 yr-old female
had a transient ischemic attack (TIA), and based on abnormal
laboratories, was diagnosed with polycythemia vera (PV). She
developed multiple thrombotic complications, including myocar-
dial infarction, cerebral vascular accident and an aortic valve
thrombus. She was initially managed with phlebotomy for 4 years,
followed by hydroxyurea for approximately 14 years. Seventeen
years into her illness, progressive massive splenomegaly necessi-
tated splenectomy. Recombinant erythropoietin was started 18
years into her illness, followed by periodic red blood cell (RBC)
transfusions to treat progressive anemia. Twenty years after her
initial PV diagnosis a bone marrow biopsy specimen conﬁrmed
post-PV MF. Four months later, she was started on thalidomide
50 mg daily and prednisone 0.5 mg/kg, reducing this dose by 50%
over the next 2 months.
Two months after starting thalidomide–prednisone, at the age
of 59 years, she was transferred to our institution with worsening
dyspnea and fatigue. Other medical history included hypertension
and hyperlipidemia. Medications included hydroxyurea, erythro-
poietin, thalidomide and prednisone. Her family history was
signiﬁcant for her father who had a myocardial infarction at theite 1020, Chicago, IL 60611,
orthwestern.edu (B.L. Stein).
Y-NC-ND license.age of 59. The patient was an active smoker with a 40 pack-yr
smoking history.
Her physical exam was notable for tachypnea, scleral icterus,
hepatomegaly and lower extremity pitting edema. Admitting
laboratories demonstrated leukocytosis with a white blood cell
count (WBC) of 68.9109/L, with a differential of 18% neutro-
phils, 2% lymphocytes, 5% monocytes, 69% eosinophils (absolute
eosinophil count of 47.5109/L), and 1% basophils. Rare blasts,
metamyelocytes, and myelocytes were noted. She required RBC
and platelet transfusion support through the course of her
hospitalization. The hepatic transaminases were normal, but the
bilirubin was 5.2 mg/dL (direct 2.4 mg/dL), and her prothrombin
time was prolonged at 16.1 s. Other pertinent labs included a
lactate dehydrogenase of 1453 units/L, and an increased troponin
I of 2.2 ng/mL.
Computed tomography images of the chest revealed ground-
glass opacities and honeycombing, suggestive of pneumonitis. She
later required intubation for respiratory failure. To evaluate the
troponin elevation, the patient had a transthoracic echocardio-
gram (Fig. 1A) that demonstrated echodense material obliterating
the right ventricular (RV) cavity, suggestive of endomyocardial
ﬁbrosis. Cardiac magnetic resonance imaging (MRI) (Fig. 1B)
revealed a RV apical thrombus and patchy RV wall enhancement
with pericardial thickening and enhancement suggestive of eosi-
nophilic myocarditis. She later developed delirium and right
upper and lower extremity weakness, and MRI of the brain
revealed multiple scattered foci of restricted diffusion, consistent
with acute ischemia from cardioembolic source, likely the known
RV thrombus.
Fig. 1. (A) Echocardiogram: Apical view. Echodense material (arrow) ﬁlling and obliterating the right ventricular cavity. This could represent thrombus or eosinophilic
inﬁltration of the heart/endomyocardial ﬁbrosis. (B) Cardiac MRI, T2-weighted. RV apical thrombus.
Fig. 2. Peripheral blood (A), bone marrow core biopsy, high power (B), and bone marrow core biopsy, low power (C) show increased eosinophilia. Reticulin stain of bone
marrow (D) reveals marked ﬁbrosis consistent with patient’s diagnosis of post-polycythemia vera myeloﬁbrosis.
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a repeat bone marrow that ruled out leukemic transformation of
her post-PVMF (Fig. 2). Unfortunately, conventional cytogenetics
could not be obtained, but ﬂuorescent in situ hybridization (FISH)
assays of the peripheral blood for BCR-ABL, CHIC2 (FIP1L1-
PDGFRa), and PDGFRB/TEL were negative
Because her clinical deterioration was attributed to hypereo-
sinophilia, she was initially started on prednisone 60 mg daily for
6 days, but subsequently received a methylprednisolone pulse of
500 mg twice daily for 3 days followed by a slow taper. Despite
high dose corticosteroids, her absolute eosinophil count remained
above 16.0109/L. Seventeen days after starting high-dose corti-
costeroids, she was started on imatinib 100 mg daily, which led to
a signiﬁcant reduction in her eosinophil count over the following
2 weeks (Fig. 3). Her steroids were tapered by approximately 50%
reductions every 5 to 6 days over the remainder of her hospita-
lization and she was discharged on prednisone 15 mg daily. On
the date of hospital discharge, her WBC was 19.1109/L with 23%
eosinophils (absolute 4.4109/L).Six months post discharge, she was clinically stable but still
required platelet and RBC transfusions; as such, her imatinib dose
was reduced to 100 mg weekly. She remained on prednisone
10 mg daily. In spite of this dose reduction in imatinib, her
absolute eosinophil count remained suppressed at 0.8109/L.2. Discussion
Our patient unfortunately experienced typical arterial thrombotic
complications of the polycythemic phase of her MPN, though this
predisposition may have been also inﬂuenced by her family history
and tobacco use. The progression to post-PVMF was accompanied by
the expected complications of this phase, requiring splenectomy for
massive splenomegaly and transfusion support for anemia. Leuko-
cytosis is also an expected complication of MF, but typically, the
myeloid expansion is characterized by a neutrophilia, with circulat-
ing immature precursors; monocytosis can be seen, along with
basophilia and eosinophilia, but the latter are not typically the
Fig. 3. Absolute eosinophil count and pharmacologic interventions over time. High dose steroids are graphed in prednisone-equivalent doses. Eosinophilia signiﬁcantly
improved after starting imatinib on day 17.
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reports of hypereosinophilia associated with PV2 and JAK2 V617F
mutations,3 but this appears to be a rare complication. The reported
case of HES associated with PV describes a 60-yr-old woman who
presented 5 years after the diagnosis of PV with systemic symptoms
of sweats, weight loss, pleuritis, and was found to have an absolute
eosinophil count of 9.7109/L.2 This case differs from ours in that
the patient also had an elevated ANA, RF, and IgE, suggesting a
possible reactive eosinophilia. She was treated with hydroxyurea and
had a dramatic response without recurrence. Another case of MF
associated with hypereosinophilia (4.8109/L) was reported in a
patient with a novel translocation, t(6;10)(q27;q11), an absence of
end-organ damage, and early progression to AML-M5a.4 In our
patient, the striking eosinophilia (47.5109/L) was an unexpected
feature of her post-PVMF, and her clinical deterioration due to
endomyocardial ﬁbrosis, cerebrovascular accident, and pneumonitis
was akin to end-organ damage as seen in patients with HES.
Eosinophilia often occurs as a secondary process due to parasitic
infections, allergy, connective tissue disease, malignancy, or drug
reactions. When secondary causes of eosinophilia are excluded, one
must consider HES, which is deﬁned as a peripheral eosinophil count
of greater than 1.5109/L on at least 2 occasions and the absence of
secondary causes.5 The syndrome includes several variants, including
myeloproliferative HES, lymphocytic HES, and organ-limited eosino-
philic disorders, some of which are overlapping. The myeloprolifera-
tive variant can display similar features as the classical MPN,
including organomegaly, marrow ﬁbrosis, clonality, increased vita-
min B12 levels, thrombotic tendencies, and AML transformation.
However, this group of illnesses is typically clinically andmolecularly
distinct from the classical MPN.
A novel fusion tyrosine kinase, FIP1L1-PDGFRa, was identiﬁed
as the most common genetic abnormality in the myeloprolifera-
tive forms of HES, and this form is responsive to imatinib.6 Our
patient was tested for the FIP1L1-PDGFRa mutation as well as
other less common mutations, none of which were present.
Although imatinib can successfully inhibit the constitutively
active tyrosine kinase created by the FIP1L1-PDGFRa rearrange-
ment and lead to a complete hematologic response in nearly 100%
of patients harboring this speciﬁc mutation,7 imatinib has alsobeen used in cases of HES without the FIP1L1-PDGFRa mutation
with limited success.8 Due to the critical illness of our patient,
severe end-organ damage from eosinophilia, and lack of signiﬁ-
cant response to high-dose steroids, our patient was treated with
imatinib, despite her negative FIP1L1-PDGFRa status. She had a
dramatic response to imatinib 100 mg daily, and her eosinophil
counts were suppressed 6 months after diagnosis of HES with
imatinib, which had been reduced to weekly dosing due to
cytopenias. Her prognosis is still guarded given the poor out-
comes associated with her underlying post-PVMF.
The mechanism accounting for our patient’s hypereosinophilia is
unexplained, as molecular testing did not reveal a characteristic
abnormality as seen in myeloproliferative forms of HES. In part
due to an inaspirable bone marrow, cytogenetics could not be
obtained, impairing recognition of clonal evolution, such as the
t(6;10)(q27;q11) in a previously described case4 or a mutation of
FGFR1, which is associated with the 8p11 myeloproliferative syn-
drome that frequently presents with eosinophilia.9 Interestingly,
JAK2, has also recently been identiﬁed as a mediator of eosinophil
growth that is activated by the FIP1L1-PDGFRa fusion gene in that
form of myeloproliferative HES.10 It is unclear whether the hyper-
eosinophilia was an isolated secondary process in our patient’s case,
but we suspect that it was a consequence of clonal evolution of her
underlying MPN, with aberrant, imatinib-sensitive tyrosine kinase
activity leading to eosinophil proliferation.Acknowledgments:
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